| scholarly article | Q13442814 |
| P2093 | author name string | Ekkernkamp A | |
| Graninger W | |||
| Legat FJ | |||
| Stengel D | |||
| Amann W | |||
| Schintler M | |||
| Görzer E | |||
| Pieber T | |||
| P2860 | cites work | Role of fosfomycin in a synergistic combination with ofloxacin against Pseudomonas aeruginosa growing in a biofilm | Q30861282 |
| Patient education for preventing diabetic foot ulceration. | Q31144068 | ||
| How frequent are diabetes-related amputations of the lower limbs in Germany? An analysis on the basis of routine data | Q33198395 | ||
| Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis | Q33982025 | ||
| Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate | Q34284305 | ||
| Clinafloxacin versus piperacillin/tazobactam in the treatment of severe skin and soft-tissue infections in adults at a Veterans Affairs medical center | Q34520874 | ||
| Penetration of fosfomycin into inflammatory lesions in patients with cellulitis or diabetic foot syndrome | Q34721887 | ||
| Biological costs and mechanisms of fosfomycin resistance in Escherichia coli | Q35685710 | ||
| Geographic variation of lower-extremity major amputation in individuals with and without diabetes in the Medicare population | Q40708582 | ||
| Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial | Q42681448 | ||
| Use of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients | Q44384585 | ||
| Target site bacterial killing of cefpirome and fosfomycin in critically ill patients | Q44468693 | ||
| Prevalence and antimicrobial susceptibility of pathogens in uncomplicated cystitis in Europe. The ECOaSENS study | Q44607483 | ||
| In vitro activity of fosfomycin against Gram-negative urinary pathogens and the biological cost of fosfomycin resistance | Q44607486 | ||
| Antibiotic resistance rates and phenotypes among isolates of Enterobacteriaceae in French extra-hospital practice | Q44778046 | ||
| A cost analysis of diabetic lower-extremity ulcers | Q44875707 | ||
| Economic costs of diabetes in the US in 2002. | Q44892463 | ||
| Introducing fosfomycin for surgical prophylaxis--emergence of resistance in aerobic faecal gram-negative bacteria of in-patients, but not among strains causing infection after elective colorectal procedures | Q45105226 | ||
| [Etiology and antimicrobial susceptibility among uropathogens causing community-acquired lower urinary tract infections: a nationwide surveillance study]. | Q45257883 | ||
| Acceptable rates of treatment failure in osteomyelitis involving the diabetic foot: a survey of infectious diseases consultants | Q47217357 | ||
| Plasmid-encoded fosfomycin resistance in bacteria isolated from the urinary tract in a multicentre survey | Q48044137 | ||
| Amdinocillin plus cefoxitin versus cefoxitin alone in therapy of mixed soft tissue infections (including diabetic foot infections) | Q48662486 | ||
| Incidence, outcomes, and cost of foot ulcers in patients with diabetes. | Q52220324 | ||
| The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results. | Q52373114 | ||
| Diabetic foot ulcer and multidrug-resistant organisms: risk factors and impact. | Q53892399 | ||
| A comparison of two diabetic foot ulcer classification systems: the Wagner and the University of Texas wound classification systems. | Q55034568 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 527-535 | |
| P577 | publication date | 2005-10-01 | |
| P1433 | published in | Journal of Chemotherapy | Q15754073 |
| P1476 | title | Second-line treatment of limb-threatening diabetic foot infections with intravenous fosfomycin | |
| P478 | volume | 17 |
| Q36363257 | Adverse Events Associated with Fosfomycin Use: Review of the Literature and Analyses of the FDA Adverse Event Reporting System Database |
| Q36835428 | Biosynthesis of fosfomycin, re-examination and re-confirmation of a unique Fe(II)- and NAD(P)H-dependent epoxidation reaction |
| Q37633415 | Fosfomycin: an old, new friend? |
| Q90477681 | Intravenous Fosfomycin: An Assessment of Its Potential for Use in the Treatment of Systemic Infections in Canada |
| Q84446167 | Management of diabetic foot infections in an era of increasing microbial resistance |
| Q27677194 | Mechanistic studies of an unprecedented enzyme-catalysed 1,2-phosphono-migration reaction |
| Q36729589 | Optimising antimicrobial therapy in diabetic foot infections |
| Q46475412 | Pharmacokinetics of a single bolus intravenous, intramuscular and subcutaneous dose of disodium fosfomycin in horses |
| Q45576659 | Pharmacokinetics of disodium fosfomycin in broilers and dose strategies to comply with its pharmacodynamics versus Escherichia coli |
| Q37642761 | Pharmacotherapy of diabetic foot osteomyelitis. |
| Q24653335 | Purification and characterization of the epoxidase catalyzing the formation of fosfomycin from Pseudomonas syringae |
| Q35959558 | Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin |
Search more.